0001179110-21-008782.txt : 20210915 0001179110-21-008782.hdr.sgml : 20210915 20210915161342 ACCESSION NUMBER: 0001179110-21-008782 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210913 FILED AS OF DATE: 20210915 DATE AS OF CHANGE: 20210915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haviland Kate CENTRAL INDEX KEY: 0001663022 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 211255565 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORPORATION STREET 2: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2021-09-13 0 0001597264 Blueprint Medicines Corp BPMC 0001663022 Haviland Kate C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Operating Officer Common Stock 2021-09-13 4 M 0 1000 36.05 A 54948 D Common Stock 2021-09-13 4 S 0 286 101.11 D 54662 D Common Stock 2021-09-13 4 S 0 261 99.98 D 54401 D Common Stock 2021-09-13 4 S 0 417 99.25 D 53984 D Common Stock 2021-09-13 4 S 0 28 98.41 D 53956 D Common Stock 2021-09-13 4 S 0 8 97.62 D 53948 D Stock Option (Right to Buy) 36.05 2021-09-13 4 M 0 1000 0 D 2027-02-16 Common Stock 1000 1591 D Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.71 to $101.69 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) in this form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.70 to $100.67 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.70 to $99.67 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.735 to $98.67 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.61 to $97.66 per share. This option was granted on February 16, 2017 and is fully vested as of the date hereof. /s/ Ariel Hurley, Attorney-in-Fact 2021-09-15